

Most complete.  
Least manipulated.

Good as

Nu

NuShield® is the  
dehydrated placental  
allograft wound covering  
that provides convenience  
without compromise.

©2020 Organogenesis Inc. OI-NUS1034. All rights reserved. Printed in U.S.A. 01/2020  
NuShield is a registered trademark of Organogenesis Inc.

Organogenesis  
**NuShield**®  
Sterilized, Dehydrated Placental Allograft


## NuShield® preserves key components to support the healing process

NuShield uses a novel preservation method that retains the native amnion and chorion layers and leaves the spongy layer intact, locking in growth factors and regulatory proteins. This enables NuShield to undergo less manipulation than other dehydrated placental allografts on the market.<sup>1,2</sup>

In vitro, the growth factors released by NuShield have been shown to<sup>2</sup>:

- Stimulate cell proliferation and migration
- Enhance angiogenesis
- Reduce inflammatory processes


The unique preservation method retains all native layers



## The complete layers of NuShield support real-world regeneration

In real-world patients (retrospective case series), NuShield was used in a wide variety of wounds (N=50), including VLUs (n=14), DFUs (n=24), and other wounds (pressure ulcers, nonhealing surgical, ischemic, mixed etiology, and nonhealing amputation; n=12).<sup>4</sup>

Median time to wound closure<sup>\*4</sup>



\* Estimated median time to complete wound closure for wounds from a Cox regression model with terms for age, sex, wound type, wound duration, baseline wound area, and duration in clinic. Test of equality over strata:  $P=0.071$  (Wilcoxon).

† All wounds includes DFUs, VLUs, and other wounds.

‡ Other includes 3 pressure injuries; 4 nonhealing surgical, 1 ischemic, and 1 mixed etiology wounds; 1 nonhealing amputation; and 1 not identified.

§ Estimated frequency of complete wound closure for all wounds from a Cox regression model with terms for age, sex, wound type, wound duration, baseline wound area, and duration in clinic. Test of equality over strata:  $P=0.071$  (Wilcoxon).

VLU=venous leg ulcer; DFU=diabetic foot ulcer

Note: NuShield is intended for use as a wound covering.

References: 1. Data on file. Description of BioLoc process. Organogenesis Inc. 2. McQuillling JP, et al. *Int Wound J*. 2019;16(3):827-840. 3. Data on file. DR-0004. Organogenesis Inc. 4. Caporusso J, et al. *Wounds*. 2019;31(4 suppl):S19-S27.

**56%** of NuShield-treated wounds achieved complete wound closure<sup>§</sup> at 16 weeks.<sup>4</sup>

**73%** of NuShield-treated wounds achieved complete wound closure<sup>§</sup> at 24 weeks.<sup>4</sup>

Give your patients the most complete, least manipulated dehydrated placental allograft.  
Learn more at [NuShieldComplete.com](http://NuShieldComplete.com)